

Amendment of the Sequence Listing

Please introduce into the application the attached pages marked "Sequence Listing." In accordance with 37 C.F.R. § 1.823(a)(1), the pages of the "Sequence Listing" are numbered independently of the numbering of the remainder of the application.

Remarks

Claims 17 and 22-35 have been amended without any intention of disclaiming equivalents thereof. Claims 1 and 36-38 have been cancelled without prejudice to their subsequent reintroduction into this application or their introduction into a related application. Claims 39 and 40 have been added. Upon entry of this paper, claims 17-35 and 39-40 will be pending and under consideration.

Support for the claim amendments can be found throughout the application as filed. The claims have been amended to modify grammar and introduce sequence identifiers. In addition, claims 22, 25, and 28 have been amended to introduce “said GHRH analogue or salt.” Support for these amendments appear, for example, in the fourth full paragraph on page 8 of the international application as published. Claims 31-35 have been amended to recite ‘method’ rather than ‘use’ claims. Claims 24, 27, 30, and 33 have been amended to modify dependencies. Support for new claims 39 and 40 can be found throughout the application as filed, for example, on page 6, lines 5-15 and in Table 1 on page 12 of the international application as published and in claim 1 in the application as filed.

Applicants have amended paragraphs in the specification to include a sequence identifier in accordance with 37 C.F.R. §1.821 and to correct typographical errors. In addition, Applicants provide a Sequence Listing in paper and computer-readable forms. The content of the paper and the computer-readable copy are the same. Applicants submit that support for the Sequence Listing is found throughout the application as filed, for example, at pages 4 and 6 of the international publication, and in the claims of the application as originally filed.


CONCLUSION

Applicants believe that the aforementioned amendments introduce no new matter. The Office is invited to contact the undersigned attorney to discuss any matters relating to the application. Early favorable action is respectfully solicited.

Respectfully submitted,

Date: February 5, 2007
Reg. No. 58,312

Tel. No.: (617) 570-1657
Fax No.: (617) 523-1231


Randall D. Morin
Attorney for Applicants
Goodwin Procter LLP
Exchange Place
Boston, Massachusetts 02109
Customer No. 051414